TrialPath

Find a study

Match me to a study

19 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

14 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, AuroraEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.Glucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownHome Based Infusions for Ocrelizumab — Amerita, CentennialStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, Baltimore